Bliss GVS Pharma Past Earnings Performance
Past criteria checks 0/6
Bliss GVS Pharma's earnings have been declining at an average annual rate of -6.3%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 2.9% per year. Bliss GVS Pharma's return on equity is 6.9%, and it has net margins of 7.9%.
Key information
-6.3%
Earnings growth rate
-6.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 2.9% |
| Return on equity | 6.9% |
| Net Margin | 7.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Bliss GVS Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 8,002 | 634 | 1,466 | 0 |
| 30 Jun 24 | 7,944 | 815 | 1,424 | 0 |
| 31 Mar 24 | 7,702 | 755 | 1,394 | 0 |
| 31 Dec 23 | 7,569 | 879 | 1,234 | 0 |
| 30 Sep 23 | 7,619 | 883 | 1,213 | 0 |
| 30 Jun 23 | 7,224 | 598 | 1,190 | 0 |
| 31 Mar 23 | 7,516 | 709 | 1,160 | 0 |
| 31 Dec 22 | 7,339 | 871 | 1,284 | 0 |
| 30 Sep 22 | 7,444 | 91 | 1,256 | 0 |
| 30 Jun 22 | 7,680 | 165 | 1,235 | 0 |
| 31 Mar 22 | 7,475 | 150 | 1,045 | 0 |
| 31 Dec 21 | 7,124 | 17 | 896 | 0 |
| 30 Sep 21 | 6,602 | 773 | 876 | 0 |
| 30 Jun 21 | 6,158 | 766 | 698 | 0 |
| 31 Mar 21 | 5,772 | 685 | 827 | 0 |
| 31 Dec 20 | 5,650 | 710 | 763 | 0 |
| 30 Sep 20 | 5,487 | 692 | 730 | 0 |
| 30 Jun 20 | 6,073 | 797 | 582 | 0 |
| 31 Mar 20 | 6,893 | 973 | 684 | 0 |
| 31 Dec 19 | 8,136 | 1,066 | 835 | 0 |
| 30 Sep 19 | 8,861 | 1,087 | 805 | 0 |
| 30 Jun 19 | 9,044 | 1,192 | 525 | 0 |
| 31 Mar 19 | 8,986 | 1,237 | 748 | 0 |
| 31 Dec 18 | 3,788 | 623 | 234 | 0 |
| 30 Sep 18 | 3,543 | 543 | 300 | 0 |
| 30 Jun 18 | 3,521 | 469 | 369 | 0 |
| 31 Mar 18 | 3,720 | 297 | 432 | 0 |
| 31 Dec 17 | 9,063 | 1,098 | 1,669 | 0 |
| 30 Sep 17 | 9,423 | 1,053 | 1,659 | 0 |
| 30 Jun 17 | 8,843 | 860 | 1,627 | 0 |
| 31 Mar 17 | 4,033 | 509 | 654 | 0 |
| 31 Dec 16 | 6,711 | 664 | 944 | 0 |
| 30 Sep 16 | 5,755 | 742 | 853 | 0 |
| 30 Jun 16 | 5,911 | 836 | 370 | 0 |
| 31 Mar 16 | 5,469 | 825 | 782 | 0 |
| 31 Mar 15 | 4,071 | 599 | 764 | 0 |
| 31 Mar 14 | 3,446 | 410 | 828 | 0 |
Quality Earnings: 506197 has a large one-off loss of ₹287.4M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 506197's current net profit margins (7.9%) are lower than last year (11.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 506197's earnings have declined by 6.3% per year over the past 5 years.
Accelerating Growth: 506197's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 506197 had negative earnings growth (-28.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20.5%).
Return on Equity
High ROE: 506197's Return on Equity (6.9%) is considered low.